Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a spot of rain. However, we are a wee bit busier than usual as we prepare to co-host an informative session today on biosimilars. Feel free to tune in and, if you care to do so, wish us luck. Meanwhile, we are busy as ever foraging for interesting items to pass along. On that note, here is the latest menu of tidbits. Hope your day is smashing and feel free to keep in touch. We appreciate the interactions …

A coalition of health industry groups unveiled a public-relations push that aims to ensure lawmakers keep their campaign-trail promises to lower drug costs, STAT explains. The campaign, which features both a 30-second and 60-second ad, was unveiled the same day that the current Congress returns to Washington for the first time since the midterm elections. The initial ads focus on insulin costs and feature a man with diabetes penning a plea to his congressman: that he follow through on a pledge to lower drug costs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy